Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp': reply from the authors.

Address: Klinik für Dermatologie, Venerologie und Allergologie, St. Josef-Hospital, Bochum, Germany.; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, U.K.; Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.; LEO Pharma A/S, Ballerup, Denmark.